SCHEMBL7013306

SCHEMBL7013306

O=C(CC[C@@H]1NC(=O)OC1=O)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
GLA P06280 1/20 0.44
LMNA P02545 1/20 0.40
CDC25B P30305 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415882 1.00 ALDH1A1 (0.45) ALDH1A1MAPK1L3MBTL1GLALMNA
SCHEMBL12086008 1.00 ALDH1A1 (0.45) ALDH1A1MAPK1L3MBTL1GLALMNA
SCHEMBL22817371 0.92 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1GLALMNA
SCHEMBL11957429 0.87 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1GLALMNA
SCHEMBL9886347 0.86 GLA (0.55) ALDH1A1MAPK1L3MBTL1GLACDC25B
SCHEMBL4413019 0.86 GLA (0.55) ALDH1A1MAPK1L3MBTL1GLACDC25B
SCHEMBL9917628 0.86 GLA (0.55) ALDH1A1MAPK1L3MBTL1GLACDC25B
SCHEMBL22817417 0.84 MEN1 (0.34) GLAKMT2A
SCHEMBL9886333 0.84 MEN1 (0.34) GLAKMT2A
SCHEMBL14901058 0.81 KMT2A (0.38) ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027218-A1 STAR-SHAPED GRAFT COPOLYMERS POLYPEPTIDE THERAPEUTIC SOLUTIONS S L (ES) 2026-01-29 US disclosed
EP-4532586-A1 STAR-SHAPED GRAFT COPOLYMERS Polypeptide Therapeutic Solutions, S.L. (ES) 2025-04-09 EP disclosed
CN-119591349-A Wear-resistant porous brick material and preparation method thereof 武汉市新明亮建筑材料有限责任公司 2025-03-11 CN disclosed
CN-119585343-A Star graft copolymers 多肽治疗解决公司 2025-03-07 CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
CN-117860908-A Double-drug nano-drug delivery system with cisplatin drug and proteinase K coupled and preparation method thereof 浙江大学长三角智慧绿洲创新中心 2024-04-12 CN disclosed
US-20240109875-A1 NOVEL METHOD FOR SYNTHESIZING NCA COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (ENSCM) (FR) 2024-04-04 US disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
WO-2023227724-A1 STAR-SHAPED GRAFT COPOLYMERS POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) 2023-11-30 WO disclosed
WO-2023227724-A1 STAR-SHAPED GRAFT COPOLYMERS POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) 2023-11-30 WO disclosed
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-04-09 US disclosed
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US disclosed
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US disclosed
WO-2008134734-A2 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 WO disclosed
WO-2008134731-A1 HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 WO disclosed
US-7294719-B2 Synthesis of amino acid, N-carboxyanhydrides SIGMA-ALDRICH CO. (US) 2007-11-13 US disclosed
US-7294719-B2 Synthesis of amino acid, N-carboxyanhydrides SIGMA-ALDRICH CO. (US) 2007-11-13 US disclosed
US-6670447-B2 An 3-acyl-4-substituted-oxazolidin-2,5-dione that readily reacts with nucleophilic reagents such as free amino acids; use in peptide synthesis for example MITSUI CHEMICALS, INC. (JP) 2003-12-30 US disclosed
EP-1298127-A1 AMINO ACID-N-CARBOXY ANHYDRIDES HVAING SUBSTITUENT AT NITROGEN Mitsui Chemicals, Inc. (JP) 2003-04-02 EP disclosed
US-20020173664-A1 Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen MITSUI CHEMICALS, INC. (JP) 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027218-A1 STAR-SHAPED GRAFT COPOLYMERS RHOA, PCNA, HBZ ALDH1A1 4727/4885MAPK1 2042/4885L3MBTL1 1255/4885
US-20240109875-A1 NOVEL METHOD FOR SYNTHESIZING NCA COMPOUNDS NPPA, NGLY1, NAAA ALDH1A1 4529/4885MAPK1 2175/4885L3MBTL1 3696/4885
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS LIPA, LPXN, CD47 ALDH1A1 3588/4885MAPK1 4603/4885L3MBTL1 3615/4885
US-20020173664-A1 Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen DNPEP, HDGF, ANPEP ALDH1A1 702/4885MAPK1 1495/4885L3MBTL1 4223/4885
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery CLTB, SLC1A5, CLTA ALDH1A1 3966/4885MAPK1 4597/4885L3MBTL1 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.